{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:34:42Z","timestamp":1784975682982,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00277-018-3418-2","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T22:28:23Z","timestamp":1530743303000},"page":"131-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Dai","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Okitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"3418_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD, for the Non-Hodgkin\u2019s Lymphoma Classification Project (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717\u2013720","journal-title":"Ann Oncol"},{"key":"3418_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536\u2013545","journal-title":"Br J Haematol"},{"key":"3418_CR3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. International Agency for Research on Cancer (IARC), Lyon"},{"key":"3418_CR4","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019\u20135032","journal-title":"Blood"},{"key":"3418_CR5","unstructured":"NCCN Clinical practice guidelines in oncology. T-cell lymphomas Version 3.2018. \n                    http:\/\/www.nccn.org\n                    \n                  . Accessed 13 March 2018"},{"issue":"suppl 5","key":"3418_CR6","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladeto M, on behalf of the ESMO Guidelines Committee (2015) Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl 5):v108\u2013v115","journal-title":"Ann Oncol"},{"key":"3418_CR7","first-page":"90","volume":"4","author":"F Obbergh Van","year":"2013","unstructured":"Van Obbergh F, Van Hoof A, Verhoef G, Dierickx D, De Wilde V, Offner F, Bron D, Sonet A, Andr\u00e9 M, Janssens A, Bonnet C, Deprijck B, Zach\u00e9e P, Kentos A, Schroyens W, Van Den Neste E (2013) Treatment of peripheral T-cell lymphomas: recommendations of the Belgian hematological society (BHS). Belg J Hematol 4:90\u2013101","journal-title":"Belg J Hematol"},{"key":"3418_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","volume":"96","author":"H Kitahara","year":"2017","unstructured":"Kitahara H, Maruyama D, Maeshima AM, Makita S, Miyamoto KI, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Tajima K, Terauchi T, Kurihara H, Taiguchi H, Komatsu N, Tobinai K (2017) Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Ann Hematol 96:411\u2013420","journal-title":"Ann Hematol"},{"key":"3418_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970\u20131976","journal-title":"J Clin Oncol"},{"key":"3418_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, His E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182\u20131189","journal-title":"J Clin Oncol"},{"key":"3418_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631\u2013636","journal-title":"J Clin Oncol"},{"key":"3418_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492\u20132499","journal-title":"J Clin Oncol"},{"key":"3418_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766\u20131771","journal-title":"Ann Oncol"},{"key":"3418_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32:1157\u20131163","journal-title":"J Clin Oncol"},{"key":"3418_CR15","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Sustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190\u20132196","journal-title":"J Clin Oncol"},{"key":"3418_CR16","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","volume":"101","author":"M Lamarque","year":"2016","unstructured":"Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Bri\u00e8re J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C (2016) Gaulard P (2016) Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica 101:e103\u2013e106","journal-title":"Haematologica"},{"key":"3418_CR17","first-page":"45","volume":"3","author":"ML Markert","year":"1991","unstructured":"Markert ML (1991) Purine nucleoside phosphorylase deficiency. Immunodefic Rev 3:45\u201381","journal-title":"Immunodefic Rev"},{"key":"3418_CR18","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1073\/pnas.071050798","volume":"98","author":"GA Kicska","year":"2001","unstructured":"Kicska GA, Long L, H\u00f6rig H, Fairchild C, Tyler PC, Furneaux RH, Schramm VL, Kaufman HL (2001) Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A 98:4593\u20134598","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3418_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/j.1349-7006.2012.02287.x","volume":"103","author":"M Ogura","year":"2012","unstructured":"Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T, Tobinai K (2012) Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T\/natural killer-cell malignancies. Cancer Sci 103:1290\u20131295","journal-title":"Cancer Sci"},{"key":"3418_CR20","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","volume":"25","author":"R Dummer","year":"2014","unstructured":"Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Kim YH (2014) Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (mycosis fungoides and S\u00e9zary syndrome). Ann Oncol 25:1807\u20131812","journal-title":"Ann Oncol"},{"key":"3418_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"3418_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"3418_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3418_CR24","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49:2869\u20132876","journal-title":"Eur J Cancer"},{"key":"3418_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as a single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomes. Ann Oncol 21:860\u2013863","journal-title":"Ann Oncol"},{"key":"3418_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","volume":"117","author":"A Zettl","year":"2002","unstructured":"Zettl A, Lee SS, R\u00fcdger T, Starostik P, Marino M, Kirchner T, Ott M, M\u00fcller-Hermelink HK, Ott G (2002) Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 117:368\u2013379","journal-title":"Am J Clin Pathol"},{"key":"3418_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3960\/jslrt.50.59","volume":"50","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, Miyake T, Tanaka J, Nabika T, Ishikura H (2010) Small bowl perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematopathol 50:59\u201363","journal-title":"J Clin Exp Hematopathol"},{"key":"3418_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/PAS.0b013e3180339f18","volume":"31","author":"O Balagu\u00e9","year":"2007","unstructured":"Balagu\u00e9 O, Martinez A, Colomo L, Rosell\u00f3 E, Garcia A, Martinez-Bernal M, Palacin A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E (2007) Epstein-Barr virus negative clonal plasma cell proliferaitons and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clincopathologic features. Am J Surg Pathol 31:1310\u20131322","journal-title":"Am J Surg Pathol"},{"key":"3418_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","volume":"138","author":"K Willenbrock","year":"2007","unstructured":"Willenbrock K, Br\u00e4uninger A, Hansmann ML (2007) Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 138:733\u2013739","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1007\/s00277-018-3455-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3418-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T13:09:39Z","timestamp":1566911379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3418-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3418-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-018-3455-x","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]},"assertion":[{"value":"13 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dai Maruyama reports research funding from Mundipharma K.K., Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Takeda, SERVIER, and Abbvie, MSD, and receiving honoraria from Mundipharma K.K., Takeda, Janssen, Eisai, Biomedis International, Celgene, Sanofi, Kyowa Hakko Kirin, Fujifilm, Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical, and Chugai Pharma. Toshiki Uchida reports receiving an honorarium from Janssen. Yoshinobu Maeda reports research funding from Chugai Pharma, Kyowa Hakko Kirin, and Ono Pharmaceutical, and an honorarium from Mundipharma K.K. Hirokazu Nagai reports research funding from Chugai Pharma, Mundipharma K.K., Eisai, Sanofi K.K., Janssen, Takeda, Ono Pharmaceutical, and Kyowa Hakko Kirin. Hirohiko Shibayama reports research funding from Takeda, Janssen, Ono Pharmaceutical, Astellas, Teijin Pharma, Shionogi, Taiho, and Mundipharma KK, and honoraria from Takeda, Celgene, Novartis, Janssen, Kyowa Hakko Kirin, and Mundipharma KK. Kiyoshi Ando reports research funding from Mundipharma K.K. Isao Yoshida reports research funding from Kyowa Hakko Kirin and Chugai Pharma, and receiving honoraria from Mundipharma K.K., Celgene, and Kyowa Hakko Kirin. Michihiro Hidaka reports research funding from Mundipharma K.K. and Chugai Pharma. Tohru Murayama reports research funding from Celltrion, and honoraria from Nippon Shinyaku, Taiho Pharma, Janssen, Siemens, Kyowa Hakko Kirin, Novartis, Celgene, Ono Pharmaceutical, Pfizer, and Bristol-Myers Squibb. Junji Suzumiya reports research funding from Kyowa Hakko Kirin, Chugai-Roche, Shinnipponkagaku-PPD, Astellas, Toyama Chemical, Eisai, Takeda, Sumitomo Dainippon, Shionogi, Taiho, Yakult, and SymBio, and receiving honoraria from Kyowa Hakko Kirin, Chugai-Roche, Janssen, Eisai, Takeda, Sumitomo Dainippon, Otsuka, Celgene, Alexion, Novartis, Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck, Ono Pharmaceutical, Eli Lilly, Shire, Gilead, and Zenyaku. Kazuo Tamura reports receiving honoraria from Ono Pharmaceutical, Kyowa Hakko Kirin, and Eli Lilly. Ryuzo Ueda reports research funding and an honorarium from Kyowa Hakko Kirin, serving as a consultant for Mundipharma K.K. and Terumo, and receiving an honorarium from Chugai Pharma. Kensei Tobinai reports receiving research funding from Mundipharma K.K., Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Takeda, Servier, and Abbvie, and honoraria from Zenyaku Kogyo, Eisai, Takeda, Mundipharma K.K., Janssen, HUYA Bioscience International, Kyowa Hakko Kirin, Celgene, Chugai Pharma, and Ono Pharmaceutical. All remaining authors declared that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declarations and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}